Effektivnost' primeneniya kandesartana pri gipertonicheskoy boleznii nefrogennoy arterial'noy gipertonii


Cite item

Full Text

Abstract

References

  1. Andersson OK, Neldham S. The antihypertensive effect and tolerability of candesartan cilexetil, a new generation angiotensin II antagonist, in comparison with losartan. Blood Press 1998; 7: 53-9.
  2. Bakris G, Gradman A, Reif M et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CALM study. J Clin Hypertens (Greenwich) 2001; 3: 16-21.
  3. Farsang C, Kawecka-Jjasziz K, Langan J et al. For the Multicentre Study Group. Antihypertensive effects and tolerability of candesartan cilexetil alone and in combination with amlodipine. Clin Drug Invest 2001; 2: 17-23.
  4. Mimran A, Aifaro V. Candesartan: nephroprotective effects and treatment of diabetic nephropathy. Drugs Today 2003; 39 (6): 439-50.
  5. Mitsunami K, Inoue S, Maeda K et al. Three-month effects of candesartan cilexetil, an angiotensin II type 1 (AT1) receptor antagonist, on left ventricular mass and hemodynamics in patients with essential hypertension. Cardiovasc Drugs Ther 1998; 12: 469-74.
  6. Блинова Е.В., Сахнова Т.А., Саидова М.А. и др. Информативность показателей ортогональной электрокардиограммы в диагностике гипертрофии левого желудочка. Тер. 2007; 4: 15-8.
  7. Meredith P. Clinical comparative trials of angiotensine II type 1 (AT1) - receptor blockers. Blood Press 2001; 10 (Suppl. 3): 11-7.
  8. Fridman K, Wysoky M, Friberg P et al. A comparison of the inhibitory effects of candesartan cilexetil, losartan and valsartan on the response to angiotensin II in hypertensive patients. Am J Hypertens 1999; 12: 135A.
  9. Zanchetti A, Omboni S, on behalf of the Italian Candesartan Study Group. Comparison of candesartan versus enalapril in essential hypertension. Am J Hypertens 2001; 14: 129-34.
  10. Parving HH, Lehnert H, Brohner-Mortensen J et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-8.
  11. Mogensen CE, Neldam S, Tikkanen I et al. Randomised controlled trial on dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: The candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000; 321: 1440-4.
  12. Wheeldon N, Viberti G, for the MARVAL Trial. Microalbuminuria reduction with valsartan, Am J Hypertens 2001; 14: 2A.
  13. Rossing K, Christensen PK, Hansen BV et al. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy. Diabetic Care 2003; 26: 150-5.
  14. Kurokawa K, Abe K, Saruta T et al. Antiproteinuric effect of candesartan cilexetil in patients with chronic glomerulonephritis. J Ren Angiotens Aldoster Syst 2002; 3 (3): 167-75.
  15. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
  16. Lewis EJ, Hunsicker LG, Clarke WR et al. Renoprotective effect of the angiotensine-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-60.
  17. Gansevoort RT, de Zeeuw D, de Long PE. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin-angiotensin system? Kidney Int 1994; 45: 861-7.
  18. Andersen S, Jacobsen P, Tarnow L et al. Time course of the antiproteinuric and antihypertensive effect of Losartan in diabetic nephropathy. Nephrol Dial Transplant 2001; 16: 771-5.
  19. Apperloo AJ, de Zeeuw D, de Long PE. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int 1994; 45 (Suppl. 45): S174-8.
  20. de Jong PE, Navis Gj, de Zeeuw D. Renoprotective therapy: titration aganist urinary protein excretion. Lancet 1999; 354: 352-3.
  21. Rossing P, Hommel E, Smidt UM et al. Reduction in albuminuria predicts diminished progression in diabetic nephropathy. Kidney Int 45 1994; (Suppl. 45): S145-9.
  22. Rossing P, Hommel E, Smidt UM et al. Reduction in albuminuria predicts a beneficial effects on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994; 37: 511-6.
  23. Gisen Group. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy. Lancet 1997; 349: 1857-63.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 83918 от 12.09.2022 г. 
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 83917 от 12.09.2022 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies